{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:47:44Z","timestamp":1774284464586,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bcmd.2024.102870","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T22:08:32Z","timestamp":1718230112000},"page":"102870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dysmorphic megakaryocytes in TAFRO syndrome: A case series from a single institute"],"prefix":"10.1016","volume":"108","author":[{"given":"Shohei","family":"Maida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ureshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Kajihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2024.102870_bb0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3960\/jslrt.53.57","article-title":"Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status","volume":"53","author":"Kawabata","year":"2013","journal-title":"J. Clin. Exp. Hematop."},{"key":"10.1016\/j.bcmd.2024.102870_bb0010","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.25554","article-title":"Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?","volume":"94","author":"Fujimoto","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2024.102870_bb0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2169\/internalmedicine.9622-22","article-title":"TAFRO syndrome: a disease requiring immediate medical attention","volume":"62","author":"Masaki","year":"2023","journal-title":"Intern. Med."},{"key":"10.1016\/j.bcmd.2024.102870_bb0020","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2024.102870_bb0025","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimura","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2024.102870_bb0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ijlh.14086","article-title":"Morphology of myeloproliferative neoplasms","volume":"45","author":"Ng","year":"2023","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.bcmd.2024.102870_bb0035","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41375-023-01861-9","article-title":"Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives","volume":"37","author":"Barosi","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2024.102870_bb0040","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/hon.2969","article-title":"Bone marrow findings of idiopathic multicentric Castleman disease: a histopathologic analysis and systematic literature review","volume":"40","author":"Belyaeva","year":"2022","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.bcmd.2024.102870_bb0045","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2024.102870_bb0050","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1309\/AJCP2UG9SGGWAHUA","article-title":"Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia","volume":"136","author":"Koopmans","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.bcmd.2024.102870_bb0055","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s42399-022-01343-6","article-title":"Atypical megakaryocyte morphology: an important diagnostic clue for JAK2 mutation\u2013associated disorders","volume":"5","author":"Rajpal","year":"2022","journal-title":"SN Compr Clin Med"},{"key":"10.1016\/j.bcmd.2024.102870_bb0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/modpathol.2011.128","article-title":"Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities","volume":"25","author":"Boiocchi","year":"2012","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bcmd.2024.102870_bb0065","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/00043426-200210000-00022","article-title":"Thrombocytopenia and megakaryocyte dysplasia: an adverse effect of valproic acid treatment","volume":"24","author":"Gesundheit","year":"2002","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.bcmd.2024.102870_bb0070","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1182\/blood-2023-187172","article-title":"STAG2 somatic mutations are associated with specific dysplastic megakaryocytic and myeloid cell features in myelodysplastic syndrome","volume":"142","author":"Wong","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2024.102870_bb0075","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Luque Paz","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2024.102870_bb0080","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2018-05-848671","article-title":"Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease","volume":"132","author":"Fajgenbaum","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2024.102870_bb0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12185-020-03008-3","article-title":"Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan","volume":"113","author":"Fujimoto","year":"2021","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bcmd.2024.102870_bb0090","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1007\/s00277-020-04275-0","article-title":"Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review","volume":"99","author":"Akiyama","year":"2020","journal-title":"Ann. Hematol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979624000482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979624000482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T19:16:21Z","timestamp":1721416581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979624000482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":18,"alternative-id":["S1079979624000482"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2024.102870","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dysmorphic megakaryocytes in TAFRO syndrome: A case series from a single institute","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2024.102870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102870"}}